IBM Patents Machine Learning Model for Pharmaceutical Drug Discovery
IBM announced that its scientists have been granted a patent on machine learning models to...
Pharnext Announces R&D Agreement with Galapagos to Generate a New Pipeline of Synergistic Drug...
Pharnext SA , a French biopharmaceutical company developing an advanced portfolio of products in the...
Titan Pharmaceuticals Receives Fda Communication On Ropinirole Implant Investigational New Drug Application
Titan Pharmaceuticals, Inc ,a company developing proprietary therapeutics for the treatment of select chronic diseases...
Sanofi and Regeneron Announce First Approval of KevzaraTM for the Treatment of Moderately
Sanofi and Regeneron Pharmaceuticals, Inc announced that Health Canada approved KevzaraTM (sarilumab), an interleukin-6 (IL-6)...
Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests...
University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2...
IBM Watson Health and Lundbeck form collaboration on technology for developing innovative medicine
H. Lundbeck A/S is collaborating with IBM's Watson Health to accelerate the development of innovative...
PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases
PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced the signing...
Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma
Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion...
Maverick Therapeutics, Takeda pharma join to drive T-cell Engagement therapeutics for cancer
Maverick Therapeutics Inc , an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited announced...
Takeda and PvP Biologics Announce Development Agreement around Novel Therapeutic for Celiac Disease
Takeda Pharmaceutical Company Limited and PvP Biologics, Inc announced a global agreement for the development...